MyFinsight

HomeCompareBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

||
||

Income Overview

Net Income
-$25,797K
EPS
-$27.59
Unit: Thousand (K) dollars
Income Statement
2026-06-30
Research and development
21,226
General and administrative
4,582
Total operating expenses
25,808
Loss from operations
-25,808
Interest income
264
Interest expense
251
Change in fair value of preferred stock tranche liability
0
Total other (income) expense, net
-2
Total other (income) expense, net
11
Net loss and comprehensive loss
-25,797
Basic EPS
-27.59
Diluted EPS
-27.59
Basic Average Shares
935,000
Diluted Average Shares
935,000
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

Interest income$264K Net loss andcomprehensive loss-$25,797K Total other (income)expense, net$11K Interest expense$251K Total other (income)expense, net-$2K Loss from operations-$25,808K Total operatingexpenses$25,808K Research and development$21,226K General andadministrative$4,582K

Latigo Biotherapeutics, Inc. (LTGO)

Latigo Biotherapeutics, Inc. (LTGO)